Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats

Toxicology and Applied Pharmacology

Volumn 147, Issue 1, 1997, Pages 151-168

  Wang, Xiaofeng ^a   Santostefano, Michael J ^a   Evans, Marina V ^b   Richardson, Vicki M ^b   Diliberto, Janet J ^b   Birnbaum, Linda S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; MODEL; NONHUMAN; PHARMACOKINETICS; RAT; TARGET ORGAN; TISSUE DISTRIBUTION; TOXICOKINETICS;

ANIMALIA;

EID: 0030725240     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8242     Document Type: Article

References (66)

1. Abraham K., Krowke R., Neubert D. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-pO. Arch. Toxicol. 62:1988;359-368.
2. 14p. Food. Cosmet. Toxicol. 13:1975;501-505.
3. Andersen M. E., Greenlee W. F. Biological determinants of TCDD pharmacokinetics and their relationship to a biological-based risk assessment. Banbury Report 35: Biological Basis for Risk Assessment of Dioxins and Related Compounds. 1991;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 291-307.
4. Andersen M. E., Mills J. J., Gargas M. L., Kedderis L., Birnbaum L. S., Neubert D., Greenlee W. F. Modeling receptor-mediated processes with dioxin: Implications for pharmacokinetics and risk assessment. Risk Anal. 13:1993;25-36.
5. Birnbaum L. S. Distribution and excretion of 2,3,7,8-tetrachlorodibenzo-p. Drug Metab. Disp. 14:1986;34-40.
6. Birnbaum L. S. The mechanism of dioxin toxicity: Relationship to risk assessment. Environ. Health Perspect. 102:1994;157-167.
7. Birnbaum L. S., Couture L. A. Disposition of octachlorodienzo-p. Toxicol. Appl. Pharmacol. 93:1986;22-30.
8. Birnbaum L. S., Decad G. M., Matthews H. B. Disposition and excretion of 2,3,7,8-tetrachlorodibenzofuran in the rat. Toxicol. Appl. Pharmacol. 55:1980;342-352.
9. Bischoff K. B. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother. Rep. 59:1975;777-793.
10. Bischoff K. B., Brown R. G. Drug distribution in mammals. Chem. Eng. Prog. Symp. Ser. 62:1966;33-45.
11. Bischoff K. B., Dedrick R. L., Zahako D. S., Longstreth J. A. Methotrexate pharmacokinetics. J. Pharm. Sci. 60:1971;1128-1133.
12. Bischoff K. B., Dedrick R. L., Zaharko D. S. Preliminary model for methotrexate pharmacokinetics. J. Pharm. Sci. 59:1970;149-154.
13. Buckley-Kedderis L., Diliberto J. J., Linko P., Goldstein J. A., Birnbaum L. S. Disposition of 2,3,7,8-tetrabromodibenzo-pp. Toxicol. Appl. Pharmacol. 111:1991a;163-172.
14. Buckley-Kedderis L. B., Diliberto J. J., Birnbaum L. S. Disposition and excretion of intravenous 2,3,7,8-tetrabromodibenzo-p. Toxicol. Appl. Pharmacol. 108:1991b;397-406.
15. Buckley-Kedderis L. B., Mills J. J., Andersen M. E., Birnbaum L. S. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p. Toxicol. Appl. Pharmacol. 121:1993;87-98.
16. Couture L. A., Elwell M. R., Birnbaum L. S. Dioxin-like effects observed in male rats following exposure to octachlorodibenzo-p. Toxicol. Appl. Pharmacol. 93:1988;31-46.
17. Curtis L. R., Kerkvliet N. I., Baecher-Steppan L., Carpenter H. M. 2,3,7,8-tetrachlorodibenzo-p. Fundam. Appl. Toxicol. 14:1990;523-531.
18. Dayneka N. L., Garg V., Jusko W. J. Comparison of four basic models of indirect pharmacodynamic response. J. Pharmacokinet. Biopharm. 21:1993;457-478.
19. Dedrick R. L. Physiological pharmacokinetics. J. Dyn. Syst. Meas. Control. Sept:1973;255-258.
20. Dedrick R. L., Bischoff K. B. Species similarities in pharmacokinetics. Fed. Proc. 39:1980;54-59.
21. Dedrick R. L., Bischoff K. B. Pharmacokinetics in application of the artificial kidney. Chem. Eng. Symp. Ser. 64:1968;32-44.
22. Dedrick R. L., Zaharko D. S., Lutz R. J. Transport and binding of methotrexatein vivo. J. Pharm. Sci. 62:1973;882-890.
23. Diliberto J. J., Akubue P. I., Luebke R. W., Birnbaum L. S. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Appl. Pharmacol. 130:1995;197-208.
24. Diliberto J. J., Jackson J. A., Birnbaum L. S. Comparison of 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Appl. Pharmacol. 138:1996;1-11.
25. Gasiewicz T. A., Rucci G. Cytosolic receptor for 2,3,7,8-tetrachlorodibenzo-p. Mol. Pharmacol. 26:1984;90-98.
26. Gasiewicz T. A., Geiger L. E., Rucci G., Neal R. A. Distribution, excretion and metabolism of 2,3,7,8-tetrachlorodibenzo-p. Drug Metab. Disp. 11:1983;397-403.
27. Hardwick J. P., Linko P., Goldstein J. A. Dose response for induction of two cytochrome P-450 isozymes and their mRNAs by 3,4,5,3′,4′,5′-hexachlorobiphenyl indicating coordinate regulation in rat liver. Mol. Pharmacol. 27:1985;676-682.
28. Holmes J. L., Pollenz R. S. Determination of Ah receptor nuclear translocator (Arnt) protein concentration and subcellular localization in hepatic and non-hepatic cell culture lines. Mol. Pharmacol. 1997.
29. Physiological Parameter Values for PBPK Models. 1994.
30. Kedderis L. B., Diliberto J. J., Birnbaum L. S. Disposition and excretion of intravenous 2, 3, 7, 8-tetrabromodibenzo-p. Toxicol. Appl. Pharmacol. 108:1991;397-406.
31. King F. G., Dedrick R. L., Collins J., Matthews H. B., Birnbaum L. S. A physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. Toxicol. Appl. Pharmacol. 67:1983;390-400.
32. Kociba R. J., Keyes D. G., Beyer J. E., Carreon R. M. Toxicologic studies of 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Occup. Med. 4:1978a;281-287.
33. Kociba R. J., Keyes D. G., Beyer J. E., Carreon R. M., Wade C. E., Dittenber D. A., Kalnis R. P., Franson L. E., Park C. N., Bernard S. D., Hummel R. A., Humiston C. G. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Appl. Pharmacol. 46:1978b;279-303.
34. Kociba R. J., Schwetz B. A. Toxicity of 2,3,7,8-tetrachlorodibenzo-p. Drug Metab. Rev. 13:1982;387-406.
35. Kohn M. C., Lucier G. W., Clark G. C., Sewall C., Tritscher A. M., Portier C. J. A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol. Appl. Pharmacol. 120:1993;138-154.
36. Kohn M. C., Sewall C. H., Lucier G. W., Portier C. J. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol. Appl. Pharmacol. 165:1996;29-48.
37. Lakshmanan M. R., Campbell B. S., Chirtel S. J., Ekarohita N., Ezekiel M. Studies on the mechanism of absorption and distribution of 2,3,7,8-tetrachlorodibenzo-p. J. Pharmacol. Exp. Ther. 239:1986;673-677.
38. Lauffenburg D. A., Lindermann J. J. Receptors-Models for Binding, Trafficking and Signalling. 1993;Oxford Univ. Press, New York.
39. Leung H. W., Ku R. H., Paustenbach D. J., Andersen M. E. A physiological-based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Lett. 42:1988;15-28.
40. Leung H. W., Paustenbach D. J., Murray F. J., Andersen M. E. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Appl. Pharmacol. 103:1990a;399-410.
41. 125p. Fundam. Appl. Pharmacol. 103:1990b;411-419.
42. Li X., Weber L. W. D., Rozman K. K. Toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p. Fundam. Appl. Toxicol. 27:1995;70-76.
43. Lutz R. J., Dedrick R. L., Zaharko D. S. Physiological pharmacokinetics: Anin vivo. Pharm. Ther. 11:1980;559-592.
44. Murphy J. E., Janszen D. B., Gargas L. Anin vitrop. J. Appl. Toxicol. 15:1995;147-152.
45. Norback D. H., Engblom J. F., Allen J. R. Tissue distribution and excretion of octachlorodibenzo-p. Toxicol. Appl. Pharmacol. 32:1975;330-338.
46. Parkinson A., Thomas P. E., Ryan D. E., Levin W. Thein vivo. Arch. Biochem. Biophys. 225:1983;216-236.
47. Poland A., Glover E., Kende A. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p. J. Biol. Chem. 251:1976;4936-4946.
48. Poland A., Knutson J. C. 2,3,7,8-tetrachlorodibenzo-p. Annu. Rev. Pharmacol. Toxicol. 22:1982;517-554.
49. Poland A., Palen D., Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Molec. Pharmacol. 46:1994;915-920.
50. 125p. Mol. Pharmacol. 36:1989;113-120.
51. Pollenz R. S. The aryl-hydrocarbon receptor, but not the aryl-hydrocarbon receptor nuclear translocator protein, is rapidly depleted in hepatic and nonhepatic culture cells exposed to 2,3,7,8-tetrachlorodibenzo-p. Mol. Pharmacol. 49:1996;391-398.
52. Roth W. L., Ernst S., Weber L. W. D., Kerecsen L., Rozman K. K. A pharmacodynamically responsive model of 2,3,7,8-tetrachlorodibenzo-p. Toxicol. Appl. Pharmacol. 127:1994;151-162.
53. Roth W. L., Freeman R. A., Wilson A. G. E. A physiologically based model for gastrointestinal absorption and excretion of chemical carried by lipids. Risk Anal. 13:1993;531-543.
54. Safe S. H. The aryl hydrocarbon (Ah) receptor. ISI Atlas Sci. 2:1988;78-83.
55. Santostefano M. J., Ross D. G., Savas U., Jefocate C. R., Birnabum L. S. Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1 and CYP1A2 proteins in rats. Biochem. Biophys. Res. Commun. 233:1997a;20-24.
56. M. J. Santostefano, X. Wang, M. J. DeVito, V. M. Richardson, D. G. Ross, L. S. Birnbaum, 1997b, A pharmacodynamic analysis of TCDD-induced cytochrome P-450 gene expression in multiple tissue: Dose- and time-dependent effects.
57. Sloop T. C., Lucier G. W. Dose-dependent elevation of Ah receptor binding by TCDD in rat liver. Toxicol. Appl. Pharmacol. 88:1987;329-337.
58. Tritscher A. M., Goldstein J. A., Portier C. J., McCoy Z., Clark G. C., Lucier G. W. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p. Cancer Res. 52:1992;3436-3442.
59. Tuey D. B., Matthews H. B. Use of a physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. Drug Metab. Dispos. 8:1980;397-403.
60. Tukey R. H., Hannah R. R., Negishe M., Nebert D. W., Eisen H. J. The Ah locus: Correlation of intranuclear appearance of induder-receptor complex with induction of cytochrome P1-450 mRNA. Cell. 31:1982;275-284.
61. Van den Berg M., De Jong Joost, Poiger H., Olson J. R. The toxicokinetics and metabolism of polychlorinated dibenzo-p. Crit. Rev. Toxicol. 24:1994;1-74.
62. Van Der Molen G. W., Kooijman S. A. L. M., Slob W. A generic toxicokinetic model for persistent lipophilic compounds in humans: An application to TCDD. Fundam. Appl. Toxicol. 31:1996;83-94.
63. Voorman R., Aust S. D. Inducers of cytochrome P-450d: Influence on microsomal catalytic activities and differential regulation by enzyme stabilization. Arch. Biochem. Biophys. 262:1988;76-84.
64. X. Wang, K. B. Bischoff, L. S. Birnbaum, 1997, Analysis of flow-limited and membrane-limited assumptions in tissue uptake with the singular perturbation method.
65. X. Wang, M. J. Santostefano, M. J. DeVito, L. S. Birnbaum, 1997, Extrapolation of a PBPK model for TCDD across routes of exposure, geneders, and from rats to mice.
66. Weber L. W. D., Ernst S. W., Stahl B. U., Rozman K. Tissue distribution and toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p. Fundam. Appl. Toxicol. 21:1993;523-534.